Keelmark

Independent by design

About

Keelmark is an independent resource on ibogaine safety, legality, and access. It exists to make difficult questions easier to examine without turning uncertainty into promises.

Hands held together in a quiet moment of consideration

01 / Why Keelmark exists

Context before conclusions.

People exploring ibogaine-related questions often encounter strong claims, incomplete caveats, and practical decisions that cannot be reduced to a simple answer. Keelmark was created to offer a calmer place to begin: an independent reference about Ibogaine Treatment Centers USA and the questions that surround access, safety, evidence, and law.

Our mission is straightforward: help people understand ibogaine’s legal status, evidence, cardiac risks, and treatment-access claims in the United States. We prioritize clear context over promises, and organize information so readers can distinguish a reported claim from a verified source or an unresolved question.

02 / Our editorial approach

How we assess information.

Keelmark draws on official records, research literature, public registries, and primary sources where they are available. When interpreting research, we aim to keep study limits visible; the ClinicalTrials.gov study registry, for example, helps readers distinguish registered research from broad marketing language.

  1. Start with the source. We look for the underlying record before repeating a claim.
  2. Keep scope visible. A finding, policy, or account is described within the limits of what it can support.
  3. Separate information from instruction. Keelmark does not diagnose, recommend treatment, or provide legal advice.

03 / What we cover

A practical map of recurring questions.

Our material is organized around the decisions people are actually trying to understand: safety considerations, legal and trial context, treatment-access claims, travel questions, and alternatives. The way Keelmark organizes its guidance is intended to make those paths easier to review without presenting a single path as right for everyone.

Some questions begin with specific experiences or stories. For readers evaluating narrative accounts, an ibogaine trip report can show what an individual describes, but it should not be treated as proof of an outcome. Personal testimony and formal evidence answer different questions.

Safety

Risk context, careful language, and the difference between a claim and a medical assessment.

Access

Questions that shape how people evaluate availability, travel, and treatment-access statements.

Evidence

Research context and source-aware framing for claims that may sound more certain than they are.

04 / Who this is for

For people who need room to think.

“Clear information does not make a decision for someone. It helps them ask better questions.”

Keelmark is for people exploring ibogaine-related questions, as well as families and professionals seeking clear U.S.-focused context. Readers comparing claims around alcohol use can examine the specific framing at whether ibogaine works for alcohol; readers weighing cross-border considerations may also encounter information about treatment centers in Canada.

We use plain language because health information can be difficult to interpret even when it is available. The National Institutes of Health health-information guidance emphasizes the value of using credible sources and understanding information before acting on it.

05 / Editorial principles

The standards we return to.

Our approach is guided by a small set of durable principles. They are designed to keep the resource useful when the available information is uneven, emotionally charged, or difficult to verify.

  • Safety before claims
  • Evidence over hype
  • Legal clarity
  • Plain language
  • Independence

When a term needs a neutral starting point, we favor definitions that can be checked. The overview of evidence-based medicine is one useful reference for the principle that evidence must be weighed alongside its limits and context.

06 / Independent by design

Information, not instruction.

Keelmark is independent of clinics and treatment providers. It does not provide medical or legal advice, and it does not replace professional assessment. Readers seeking a broader overview can return to the context around the psychedelic drug ibogaine while keeping source quality and uncertainty in view.

Explore the resource